Poster Number
30
Poster Title
Harmonising Genomic Insights from Clinical Practice: WAYFIND-R's Approach to Global Clinico-Genomic Data Collection and Collaboration
Authors
Melanie Courtot,1 Helene Schlecht,2 Jean-Yves Blay,3 Rodrigo Dienstmann,4
Allan Hackshaw,5 Jan Geissler,6 Ana Ferro,7 Anna Ledwon,8 Tom Stone,7
Erika Schirghuber,9 Christophe Le Tourneau10
1 Ontario Institute for Cancer Research, Toronto, ON, Canada;
2 NW Genomic Laboratory Hub, Manchester University NHS Foundation Trust, Manchester, UK;
3 Centre Léon Bérard and Université Claude Bernard, Lyon, France;
4 Oncoclínicas Group, São Paulo, Brazil; and University of Vic – Central University of Catalonia, and Vall d’Hebron Institute of Oncology, Barcelona, Spain;
5 UCL Cancer Institute, London, UK;
6 Patvocates GmbH, Riemerling, Germany;
7 Roche Products Limited, Welwyn Garden City, UK;
8 Square One Resources Poland, Warsaw, Poland by order of Roche Polska Sp. z o.o., Warsaw, Poland;
9 F. Hoffmann-La Roche Ltd, Basel, Switzerland;
10 Institut Curie, Paris, France.
Allan Hackshaw,5 Jan Geissler,6 Ana Ferro,7 Anna Ledwon,8 Tom Stone,7
Erika Schirghuber,9 Christophe Le Tourneau10
1 Ontario Institute for Cancer Research, Toronto, ON, Canada;
2 NW Genomic Laboratory Hub, Manchester University NHS Foundation Trust, Manchester, UK;
3 Centre Léon Bérard and Université Claude Bernard, Lyon, France;
4 Oncoclínicas Group, São Paulo, Brazil; and University of Vic – Central University of Catalonia, and Vall d’Hebron Institute of Oncology, Barcelona, Spain;
5 UCL Cancer Institute, London, UK;
6 Patvocates GmbH, Riemerling, Germany;
7 Roche Products Limited, Welwyn Garden City, UK;
8 Square One Resources Poland, Warsaw, Poland by order of Roche Polska Sp. z o.o., Warsaw, Poland;
9 F. Hoffmann-La Roche Ltd, Basel, Switzerland;
10 Institut Curie, Paris, France.
Abstract
WAYFIND-R (NCT04529122) collects longitudinal clinico-genomic data from patients with solid tumours profiled with next-generation sequencing (NGS) during routine care, with the aim of improving understanding of NGS-based treatment decisions, health outcomes and healthcare access disparities.
Differences in reporting of NGS results in clinical practice pose a challenge and limit insight generation. These include different formats/nomenclatures across providers, laboratories, regulators, and countries; NGS tests used (panel sizes; or hotspot, whole genome, whole exome, DNA or RNA sequencing); and samples used (tissue or liquid biopsies). To standardise genomic data collection reflecting molecular profiling information available to Molecular Tumour Boards and clinicians to guide treatment decisions, a team of clinicians, pathologists, epidemiologists and patients defined key variables for the WAYFIND-R registry. The variables include information on genomic alterations/signatures from different NGS test result reports from commercial or academic laboratory-developed tests for clinical use.
A framework was established to harmonise genomic data from >140 NGS assays at >120 hospitals across 32 countries in Europe, the Middle East and Africa, Asia–Pacific, and Latin and North America. Steps were implemented to harmonise NGS results from diverse data sources. Gene names from NGS assay specifications and test results are aligned with the Human Genome Organization Gene Nomenclature Committee ID. Validation checks are performed to verify that biospecimens match NGS tests and test results. Results are embedded into a data quality oversight framework to assess quality at each processing step along the entire data lifecycle.
Interoperable and shareable data allow WAYFIND-R to bridge clinical practice and research, supporting global research collaborations. The WAYFIND-R® Data Sharing and Collaboration Platform provides researchers with controlled access to standardised, anonymised, analysis-ready datasets in the Observation Medical Outcomes Partnership common data model, and analytical tools, in a secure processing environment to ensure privacy and security of health data.
Differences in reporting of NGS results in clinical practice pose a challenge and limit insight generation. These include different formats/nomenclatures across providers, laboratories, regulators, and countries; NGS tests used (panel sizes; or hotspot, whole genome, whole exome, DNA or RNA sequencing); and samples used (tissue or liquid biopsies). To standardise genomic data collection reflecting molecular profiling information available to Molecular Tumour Boards and clinicians to guide treatment decisions, a team of clinicians, pathologists, epidemiologists and patients defined key variables for the WAYFIND-R registry. The variables include information on genomic alterations/signatures from different NGS test result reports from commercial or academic laboratory-developed tests for clinical use.
A framework was established to harmonise genomic data from >140 NGS assays at >120 hospitals across 32 countries in Europe, the Middle East and Africa, Asia–Pacific, and Latin and North America. Steps were implemented to harmonise NGS results from diverse data sources. Gene names from NGS assay specifications and test results are aligned with the Human Genome Organization Gene Nomenclature Committee ID. Validation checks are performed to verify that biospecimens match NGS tests and test results. Results are embedded into a data quality oversight framework to assess quality at each processing step along the entire data lifecycle.
Interoperable and shareable data allow WAYFIND-R to bridge clinical practice and research, supporting global research collaborations. The WAYFIND-R® Data Sharing and Collaboration Platform provides researchers with controlled access to standardised, anonymised, analysis-ready datasets in the Observation Medical Outcomes Partnership common data model, and analytical tools, in a secure processing environment to ensure privacy and security of health data.
Digital Poster